What the trial was testing
The ACHIEVE-1 enrolled 559 patients with type 2 diabetes. The study was sponsored by Eli Lilly and Company and tracked outcomes across the full group of patients who matched the trial's eligibility profile.
It was a large trial designed to confirm whether the treatment works well enough for wider use. Trials at this stage are designed to produce evidence regulators and physicians can act on — not just observations to follow up later.
What the results showed
People taking orforglipron lowered their A1C by up to 1.5 percentage points after 40 weeks.
The New England journal of medicine · 2025 · NCT05971940
These findings — that orforglipron lowered A1C by about 1 to 1.5 points more than placebo — were published in the The New England journal of medicine and represent the headline result of the study.
Researchers tracked outcomes across 559 patients enrolled in the trial. The result was consistent enough across the group that the team felt confident reporting it.
What this means for patients
For patients with type 2 diabetes, this result changes the calculus on what to ask their care team about. Whether it changes day-to-day care depends on factors like disease subtype, prior treatments, and where the patient is in their care journey.
What you can do now
This was a large-scale study and the results were positive. Orforglipron is not yet FDA-approved but is in late-stage testing. If you have type 2 diabetes and are interested in new treatment options, talk with your doctor about this medication or similar GLP-1 treatments that are already available.
Eligibility for the treatments mentioned above depends on specific test results and clinical history. Bring this summary, the trial name, and your most recent labs or pathology report to your next visit.
Open type 2 diabetes trials
OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme
The OBESIAL (Obesity Structured Intervention in Algeria) study aims to evaluate the clinical, metabolic, and organisational impact of a structured multidisciplinary obesity care pathway implemented under real-world conditions.
A Phase 1b Study of QX1206 in T2DM Patients With NAFLD
This is an open label phase 1b trial of QX1206 in patients with T2DM and with NAFLD. Laboratory tests and other measurements will be assessed prior to the first dose of study treatment and throughout the study to determine the recommended phase 2 dose. In addition, the preliminary effects of QX1206 on antidiabetic activity and other metabolic parameters will also be evaluated.